Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | NOS2 | P35228 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19803890 | 0.83 | NOS1 (0.51) | NOS3NOS1NOS2GSROTC | |
| SCHEMBL7785352 | 0.83 | NOS3 (0.47) | NOS3NOS1NOS2CYP2C19THPO | |
| SCHEMBL7984675 | 0.83 | NOS3 (0.47) | NOS3NOS1NOS2CYP2C19THPO | |
| SCHEMBL919222 | 0.80 | KDM4E (0.56) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL180969 | 0.80 | KDM4E (0.56) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL236178 | 0.80 | KDM4E (0.56) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL20643482 | 0.80 | GSR (0.57) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL9875639 | 0.80 | GSR (0.57) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL357483 | 0.80 | GSR (0.57) | NOS3NOS1NOS2CYP2C19GSR | |
| SCHEMBL826656 | 0.79 | GSR (0.52) | NOS3NOS1NOS2CYP2C19GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207822-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | NOS3 579/4885NOS1 1788/4885NOS2 1986/4885 |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | NOS3 459/4885NOS1 1769/4885NOS2 1784/4885 |
| US-20200207822-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | NOS3 904/4885NOS1 2369/4885NOS2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.